Hyperthyroidism is mainly due to autoimmune thyroid disorders or toxic goiter, and very rarely to the presence of thyrotropin (TSH)-secreting pituitary adenomas (TSHomas). These tumors are characterized by high levels of circulating free thyroid hormones (FT4 and FT3) in the presence of nonsuppressed serum TSH concentrations. Failure to correctly diagnose TSHomas may result in inappropriate thyroid ablation, which results in a significant increase of pituitary tumor mass. The diagnosis is mainly achieved by measuring TSH after T3 suppression and TRH stimulation tests. These dynamic tests, together with pituitary imaging and genetic testing are useful in distinguishing TSHomas from the syndromes of resistance to thyroid hormone action. The treatment of choice is surgery. In cases of surgical failure, somatostatin analogs have been found to be effective in normalizing TSH secretion in more than 90% of patients.

Keywords:
Thyrotropin-secreting pituitary adenoma, Central hyperthyroidism, Thyrotropin, Resistance to thyroid hormones, Transsphenoidal surgery, Somatostatin analogs
1.
Gershengorn MC, Weintraub BD: Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of ‘inappropriate secretion of TSH'. J Clin Invest 1975;56:633-642.
2.
Beck-Peccoz P, Brucker-Davis F, Persani L, et al: Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610.
3.
Beck-Peccoz P, Persani L, Mannavola D, Campi I: Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:597-606.
4.
Refetoff S, Dumitrescu AM: 2010 Resistance to thyroid hormone; in: Thyroid Disease Manager, chapter 16D (http://www.thyroidmanager.org).
5.
Gurnell M, Visser TJ, Beck-Peccoz P, Chatterjee VKK: Resistance to thyroid hormone; in Jameson LJ, DeGroot LJ (eds): Endocrinology, Adult and Pediatric, ed 6. Philadelphia, Saunders Elsevier, 2010, vol II, pp 1745-1759.
6.
Jailer JW, Holub DA: Remission of Graves' disease following radiotherapy of a pituitary neoplasm. Am J Med 1960;28:497-499.
7.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al: Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
8.
Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schunemann HJ: Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, ed 8. Chest 2008;133(6 suppl):123S-131S.
9.
Onnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF: National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 2013;98:626-635.
10.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-4775.
11.
Fernandez A, Karavitaki N, Wass JA: Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72:377-378.
12.
Raappana A, Koivukangas J, Ebeling T, Pirilä T: Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010;95:4268-4275.
13.
Corbetta S, Pizzocaro A, Peracchi M, Beck-Peccoz P, Faglia G, Spada A: Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin Endocrinol (Oxf) 1997;47:507-512.
14.
Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, et al: Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010;95:E373-E383.
15.
Ma W, Ikeda H, Watabe N, Kanno M, Yoshimoto T: A plurihormonal TSH-producing pituitary tumor of monoclonal origin in a patient with hypothyroidism. Horm Res 2003;59:257-261.
16.
Herman V, Drazin NZ, Gonsky R, Melmed S: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-55.
17.
Asteria C, Anagni M, Persani L, Beck-Peccoz P: Loss of heterozigosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas. J Endocrinol Invest 2001;24:796-801.
18.
Dong Q, Brucker-Davis F, Weintraub BD, Smallridge RC, Carr FE, Battey J, et al: Screening of candidate oncogenes in human thyrotrope tumors: absence of activating mutations of the Gαq, Gα11, Gαs, or thyrotropin-releasing hormone receptor genes. J Clin Endocrinol Metab 1996;81:1134-1140.
19.
Gittoes NJ, McCabe CJ, Verhaeg J, Sheppard MC, Franklyn JA: 1998 An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors. Thyroid 1998;8:9-14.
20.
Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, Zhang M, et al: Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 2001;15:1529-1538.
21.
Tagami T, Usui T, Shimatsu A, Beniko M, Yamamoto H, Naruse M: Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. J Clin Endocrinol Metab 2011;96:E948-E952.
22.
Brown RL, Muzzafar T, Wollman R, Weiss RE: A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol 2006;154:639-643.
23.
Socin HV, Chanson P, Delemer B, et al: The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003;148:433-442.
24.
Bertherat J, Brue T, Enjalbert A, Gunz G, et al: Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 1992;75:540-546.
25.
Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD: Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476-486.
26.
Clarke MJ, Erickson D, Castro MR, Atkinson JL: Thyroid-stimulating hormone pituitary adenomas. J Neurosurg 2008;109:17-22.
27.
Sanno N, Teramoto A, Osamura RY: Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neurooncol 2001;54:179-186.
28.
Gurnell M, Halsall DJ, Chatterjee VK: What should be done when thyroid function tests do not make sense? Clin Endocrinol (Oxf) 2011;74:673-678.
29.
Beck-Peccoz P, Persani L: Thyrotropin-secreting pituitary adenomas; in: Thyroid Disease. www.thyroidmanager.org.
30.
Beck-Peccoz P, Persani L: TSH-producing adenomas; in Jameson JL, DeGroot LJ (eds): Endocrinology, ed 5. Philadelphia, Saunders, 2010.
31.
Beck-Peccoz P, Persani L, Faglia G: Glycoprotein hormone α-subunit in pituitary adenomas. Trends Endocrinol Metab 1992;3:41-45.
32.
Beck-Peccoz P, Roncoroni R, Mariotti S, et al: G Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab 1990;71:19-25.
33.
Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P: Serum levels of carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol (Oxf) 1997;47:207-214.
34.
Mannavola D, Persani L, Vannucchi G, et al: Different response to chronic somatostatin analogs in patients with central hyperthyroidism. Clin Endocrinol (Oxf) 2005;62:176-181.
35.
Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P: Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3086-3090.
36.
Fliers E, van Furth WR, Bisschop PH: Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin Endocrinol (Oxf) 2012;77:788-790.
© 2013 European Thyroid Association Published by S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.